T
Tilo Biedermann
Researcher at Technische Universität München
Publications - 503
Citations - 14877
Tilo Biedermann is an academic researcher from Technische Universität München. The author has contributed to research in topics: Medicine & Immune system. The author has an hindex of 59, co-authored 437 publications receiving 12098 citations. Previous affiliations of Tilo Biedermann include Novartis & Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter,Toni Weinschenk,Arnulf Stenzl,Romuald Zdrojowy,Anna Pluzanska,Cezary Szczylik,Michael Staehler,Wolfram Brugger,Pierre-Yves Dietrich,Regina Mendrzyk,Norbert Hilf,Oliver Schoor,Jens Fritsche,Andrea Mahr,Dominik Maurer,Verona Vass,Claudia Trautwein,Peter Lewandrowski,Christian Flohr,Heike Pohla,Janusz J. Stanczak,Vincenzo Bronte,Susanna Mandruzzato,Tilo Biedermann,Graham Pawelec,Evelyna Derhovanessian,Hisakazu Yamagishi,Tsuneharu Miki,Fumiya Hongo,Natsuki Takaha,Kosei Hirakawa,Hiroaki Tanaka,Stefan Stevanovic,Jurgen Frisch,Andrea Mayer-Mokler,Alexandra Kirner,Hans-Georg Rammensee,Carsten Reinhardt,Harpreet Singh-Jasuja +38 more
TL;DR: Among six predefined populations of myeloid-derived suppressor cells, two were prognostic for overall survival, and among over 300 serum biomarkers, apolipoprotein A-I (APOA1) and chemokine (C-C motif) ligand 17 (CCL17) as being predictive for both immune response to IMA901 and overall survival are identified.
Journal ArticleDOI
EAACI Molecular Allergology User's Guide.
Paolo Maria Matricardi,Jörg Kleine-Tebbe,Hans Jürgen Hoffmann,Rudolf Valenta,Christiane Hilger,Stephanie Hofmaier,Rob C. Aalberse,Ioana Agache,Riccardo Asero,Barbara Ballmer-Weber,Domingo Barber,Kirsten Beyer,Tilo Biedermann,M. B. Bilò,Simon Blank,Barbara Bohle,Philipp P. Bosshard,Heimo Breiteneder,Helen A. Brough,Luis Caraballo,J-C Caubet,Reto Crameri,Janet M. Davies,Nikolaos Douladiris,M. Ebisawa,Philippe Eigenmann,Montserrat Fernandez-Rivas,Fatima Ferreira,Gabriele Gadermaier,Martin Glatz,Robert G. Hamilton,Thomas Hawranek,P W Hellings,Karin Hoffmann-Sommergruber,Thilo Jakob,Uta Jappe,Marek Jutel,Sandip D. Kamath,Edward F. Knol,Peter Korošec,Annette Kuehn,Gideon Lack,Gideon Lack,Andreas L. Lopata,Mika J. Mäkelä,Martine Morisset,Verena Niederberger,Anna Nowak-Wegrzyn,Nikolaos G. Papadopoulos,Elide A. Pastorello,Gabrielle Pauli,Thomas A.E. Platts-Mills,Daniela Posa,Lars K. Poulsen,Monika Raulf,Joaquín Sastre,Enrico Scala,Johannes Schmid,Peter Schmid-Grendelmeier,M. van Hage,R. van Ree,Stefan Vieths,Richard W. Weber,Magnus Wickman,Antonella Muraro,Markus Ollert +65 more
TL;DR: The European Academy of Allergy and Clinical Immunology (EAACI) Molecular Allergology User's Guide (MAUG) as mentioned in this paper provides comprehensive information on important allergens and describes the diagnostic options using component-resolved diagnosis (CRD).
Journal ArticleDOI
Cellular and molecular immunologic mechanisms in patients with atopic dermatitis
Thomas Werfel,Jean-Pierre Allam,Tilo Biedermann,Kilian Eyerich,Stefanie Gilles,Emma Guttman-Yassky,Wolfram Hoetzenecker,Edward F. Knol,Hans-Uwe Simon,Andreas Wollenberg,Thomas Bieber,Roger Lauener,Peter Schmid-Grendelmeier,Claudia Traidl-Hoffmann,Cezmi A. Akdis +14 more
TL;DR: Best evidence of the clinical efficacy of novel immunologic approaches using biological agents in patients with AD is available for the anti-IL-4 receptor α-chain antibody dupilumab, but a number of studies are currently ongoing with other specific antagonists to immune system players.
Journal ArticleDOI
Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease
Kamran Ghoreschi,Peter Thomas,Susanne Breit,Martin Dugas,Reinhard Mailhammer,Willem van Eden,Ruurd van der Zee,Tilo Biedermann,Jörg C. Prinz,Matthias Mack,Ulrich Mrowietz,Enno Christophers,Detlef Schlöndorff,Gerd Plewig,Christian A. Sander,Martin Röcken,Martin Röcken +16 more
TL;DR: IL-4 therapy can induce Th2 differentiation in human CD4+ T cells and has promise as a potential treatment for psoriasis, a prototypic Th1-associated autoimmune disease.
Journal ArticleDOI
Mast Cells Control Neutrophil Recruitment during T Cell–Mediated Delayed-Type Hypersensitivity Reactions through Tumor Necrosis Factor and Macrophage Inflammatory Protein 2
Tilo Biedermann,Manfred Kneilling,Reinhard Mailhammer,K.L. Maier,Christian A. Sander,George Kollias,Steven L. Kunkel,Lothar Hültner,Martin Röcken +8 more
TL;DR: Analysis of hapten-induced DTHRs of the skin found that mast cells determine the T cell–dependent PMN recruitment through two mediators, tumor necrosis factor (TNF) and the CXC chemokine macrophage inflammatory protein 2 (MIP-2), the functional analogue of human interleukin 8.